Shareholder Tools

Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1999
Press Releases
Date Title and Summary View
Jun 2, 2017 - Company Continuing EC1169 Program in Taxane-Exposed Patients, but Ending Clinical Development of EC1456 and of EC1169 in Taxane-Naïve Patients -¬† - Refocusing Efforts on Chimeric Antigen Receptor T-cell (CAR T-cell) and Dual-Targeted DNA Crosslinker Drug EC2629 Programs¬†- - Restructuring to Reduce Workforce by Approximately 40%; Will M...
May 26, 2017 WEST LAFAYETTE, Ind., May 26, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2017 American Society of...
May 10, 2017 WEST LAFAYETTE, Ind., May 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the first quarter ending March 31, 2017, and provided a clinical and pipeline update. "We look...
May 3, 2017 WEST LAFAYETTE, Ind., May 03, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 10th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast o...
Apr 5, 2017 - Late-breaking poster demonstrates that Endocyte's bi-specific adaptor molecules can mitigate or eliminate cytokine storms - - Potential to meaningfully improve the safety and tolerability of CAR T-cell therapies - WEST LAFAYETTE, Ind., April 05, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small m...
Mar 27, 2017 WEST LAFAYETTE, Ind., March 27, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that eight posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annu...
Mar 10, 2017 WEST LAFAYETTE, Ind., March 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the fourth quarter ending December 31, 2016, and provided a clinical and business update. "W...
Mar 10, 2017 Collaboration pairs leading SMDC technology with recognized CAR T-cell research expert Plans to develop next generation CAR T-cell therapeutic platform with potential for improved safety and efficacy in solid tumor indications WEST LAFAYETTE, Ind., March 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing ...
Mar 2, 2017 WEST LAFAYETTE, Ind., March 02, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Friday, March 10th, at 8:30 a.m. EST to discuss its fourth quarter and full year financial results and provide an operational update. Investors and the general public are invited to listen to ...
Mar 1, 2017 WEST LAFAYETTE, Ind., March 01, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the Cowen and Company 37th Annual Health Care Conference on Wednesda...
1
... NextLast
Add to Briefcase = add release to Briefcase